Table 1.

Selected clinical trials evaluating the safety, tolerability and efficacy of potential NK IRs for Multiple Myeloma NK cell-based immunotherapy (access date: August 10, 2020).

Receptor	Trial	Disease	Drugs	Phase	Participants	Results	Last Update Posted
KIR	NCT01217203	Relapsed multiple myeloma	IPH2101, Lenalidomide	I	15	Complete; Objective response in 5 patients; Severe adverse events in 5 patients; No autoimmunity	February 28, 2014
	NCT01222286	Smoldering multiple myeloma	IPH2101	II	30	Complete; No objective response; Adverse events in all patients	May 9, 2014
	NCT00999830	Multiple myeloma	IPH2101	II	27	Completed; Primary response in one patient (based on M-protein); Adverse events in 25 of 27 patients	March 24, 2016
	NCT00552396	Multiple myeloma	Anti-KIR (1-7F9)	I	32	Complete; No dose-limiting toxicity; Severe adverse event in 1 patient; Increased patient NK cell cytotoxicity against MM ex vivo	March 31, 2016
	NCT02252263	Multiple myeloma	Elotuzumab, Lirilumab, Urelumab	I	44	Complete; No results	November 1, 2017
	NCT01592370	Non-Hodgkin’s lymphoma, Hodgkin lymphoma, multiple myeloma	Nivolumab, Ipilimumab, Lirilumab, Daratumumab, Pomalidomide, Dexamethasone	I/II	375	Ongoing	May 18, 2020
	NCT01248455	Multiple myeloma, smoldering multiple myeloma	Anti-KIR	II	9	Terminated; Lack of patients meeting primary objective (50% decline in M-protein)	November 19, 2019
NKG2A	NCT02921685	Hematologic malignancies	Monalizumab	I	18	Ongoing	September 19, 2018
LAG-3/TIGIT	NCT04150965	Relapsed refractory multiple myeloma	Elotuzumab, Pomalidomide, Dexamethasone, Anti-LAG-3, Anti-TIGIT	I/II	104	Ongoing	July 7, 2020
PD1	NCT02903381	Smoldering multiple myeloma	Nivolumab, Lenalidomide, Dexamethasone	II	41	Suspended; Safety concerns	July 21, 2020
	NCT02636010	Multiple myeloma	Pembrolizumab	II	20	Complete; No results	April 29, 2020
	NCT02331368	Multiple myeloma	Autologous Stem Cell Transplant, Melphalan, Lenalidomide, MK-3475	II	32	Terminated; Complete response in 7 of 23 evaluable patients; Severe adverse events in 14 of 32 total patients	July 27, 2018
	NCT03848845	Multiple myeloma	GSK2857916, Pembrolizumab	II	40	Ongoing	August 5, 2020
	NCT03605719	Recurrent plasma cell myeloma	Carfilzomib, Dexamethasone, Nivolumab, Pelareorep	I	62	Ongoing	November 25, 2019
	NCT03530683	Lymphoma, multiple myeloma	TTI-622, Rituximab, PD-1 Inhibitor, Proteasome-inhibitors	I	156	Ongoing	September 12, 2019
	NCT03111992	Multiple myeloma	PDR001, CJM112, LCL161	I	26	Complete; No results	April 21, 2020
	NCT03357952	Multiple myeloma	Daratumumab, JNJ-63723283	II/III	10	Ongoing; All patients with treatment emergent adverse events; No dose limiting toxicity so far	January 3, 2020
	NCT03221634	Multiple myeloma	Pembrolizumab, Daratumumab	II	0	Withdrawn; Business reasons	March 25, 2019
	NCT03292263	Multiple myeloma	Melphalan, Nivolumab, Autologous Stem Cell Transplantation	I/II	30	Ongoing	March 17, 2020
	NCT02906332	Multiple myeloma	Pembrolizumab, Lenalidomide, Dexamethasone	II	16	Ongoing; Combination is well tolerated; Preliminary data show potential efficacy	January 31, 2020
	NCT02807454	Multiple myeloma	Daratumumab, Durvalumab, Pomalidomide, Dexamethasone	II	37	Ongoing	July 2, 2020
	NCT02685826	Multiple myeloma	Durvalumab, Lenalidomide, Dexamethasone	I/II	56	Ongoing; Majority of patients with adverse events; Dose-limiting toxicity in 2 patients	April 27, 2020
	NCT02616640	Multiple myeloma	Durvalumab, Pomalidomide, Dexamethasone	I	114	Ongoing	April 17, 2020
	NCT02576977	Multiple myeloma	Pembrolizumab, Pomalidomide, Dexamethasone	III	251	Terminated; Anti-PD1 treatment combination had unfavourable benefit-risk profile in relapsed refractory multiple myeloma	July 31, 2020
	NCT02579863	Multiple myeloma	Pembrolizumab, Lenalidomide, Dexamethasone	III	310	Terminated; Anti-PD1 treatment combination had unfavourable benefit-risk profile in newly diagnosed multiple myeloma	August 3, 2020
	NCT02289222	Multiple myeloma	MK-3475, Pomalidomide, Dexamethasone	I/II	48	Terminated; Due to inclusion of an IMiD in combination with pembrolizumab	November 5, 2019
	NCT02077959	Multiple myeloma	Lenalidomide, Pidilizumab	I/II	20	Complete; No results	May 30, 2019
	NCT02036502	Multiple myeloma	Pembrolizumab, Lenalidomide, Dexamethasone, Carfilzomib	I	77	Complete; Tolerable safety profile; Notable anti-tumor activity	July 13, 2020
	NCT02726581	Multiple myeloma	Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone	III	348	Ongoing	August 10, 2020